Deep Tech Meets Oncology
Bengaluru-based 4baseCare has successfully closed a Rs 128 crore ($13.3 million) funding round to accelerate its mission of democratizing precision oncology. The capital injection includes a fresh Rs 38 crore top-up led by growX Ventures and Infosys, following an initial Rs 90 crore Series B close earlier this year.
The Product: OncoTwin
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare specializes in AI-powered clinical decision support. Their flagship platform, OncoTwin, synthesizes clinico-genomic data with real-world patient insights to provide oncologists with actionable, data-driven treatment strategies.
Expansion Roadmap
- Global Footprint: Currently active in India, Dubai, Nepal, and the Philippines.
- Scaling Operations: The startup plans to enter 8-10 new countries within the next 12-18 months.
- Infrastructure: Heavy emphasis on the ‘in-hospital’ genomics lab model, with current institutional partners including AIIMS Jammu, Max Healthcare, and Shankara Hospital.
- Operational Growth: The company currently processes 1,500 tests per month, with targets to scale to 8,000–10,000 monthly tests.
Market Context
Investors are increasingly bullish on cancer-tech as it moves from experimental research to essential clinical infrastructure. With competitors like MOC Cancer Care and Everhope Oncology raising significant capital, the market is signaling that the next wave of healthtech winners will be those who successfully combine proprietary genomics databases with AI-led diagnostic workflows in emerging markets.
Founder Takeaway
4baseCare’s ability to secure follow-on funding from strategic investors like Infosys demonstrates the importance of building ‘sticky’ infrastructure—by embedding their labs directly into major hospitals, they move beyond software-as-a-service into essential clinical operations, creating a significant competitive moat.